Among the immune cells that contribute to anti-tumoral responses, conventional T cells (T cells that express an αβ T cell receptor, as well as a co-receptor CD4 or CD8), have attracted the attention of tumor immunologists and clinical scientists. The gene discussed is CD8A; the disease is neoplasm.